Aspire Biopharma Holdings Inc. is an early stage technical company. Originally formed in September 2021, the Company engaged in the business of developing and marketing the disruptive technology for the sublingual delivery of drugs and supplements.

The Company has developed and acquired disruptive technologies that address emergencies and drug efficacy, dosage management, and response time.

In March 2023, the Company filed application number 63/456,290 with the United States Patent and Trademark Office (“USPTO”) with the goal of securing patent protection for its new technology and aspirin formulation.This technology will facilitate development of any number of products in a soluble, PH neutral, fast acting powder form which has been developed by using our patent-pending formulation, and “trade secret” process. Aspire’s drug delivery comes from a new mechanism of action (absorption pathway) which allows for rapid absorption in the mouth. This provides rapid treatment impact and also allows high dose absorption.

Aspire’s patent-pending delivery system includes components specifically formulated to allow rapid sublingual absorption of drugs and supplements into the blood stream, thus by-passing the gastrointestinal tract.

A second patent for high-dose aspirin using a new micelle-based technology was filed on October 23, 2024 under application number 63/702,381. This mechanism of delivery will allow for many more substances to be absorbed sublingually. More patents will follow.